Compare BioNano Genomics Inc (BNGO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs T Rowe Price Group Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while T Rowe Price Group Inc trades at $111.32 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 1776× BioNano Genomics Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | TROW | |
|---|---|---|
Market Cap | $13.66M | $24.26B |
Sector | Health | Financials |
52-Week High | $4.92 | $121.68 |
52-Week Low | $1.06 | $86.19 |
Enterprise Value | $16.26M | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
T. Rowe Price Group (TROW) trades at $113.77, down 0.22% on the day, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a 29.26% net income margin and a P/E of 11.42, indicating potential undervaluation. Recent Q2 2026 earnings beat expectations at $2.57 per share, supported by record assets under management and higher advisory fees, though expenses and net outflows remain headwinds.
The outlook is cautiously optimistic with earnings growth and dividend stability offering upside, but risks include expense pressures and market volatility. Analyst consensus is a Hold with a $112.17 price target, near the current price, suggesting limited near-term momentum. Institutional activity shows mixed positioning, reflecting balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
